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Edited by Beat ImhofAbstract We have analyzed transcription proﬁles in peripheral
blood CD3+ cells from patients with allergic diseases to better
understand the genes that are involved. Transcription levels of
the gene KIAA0603/AS160 in CD3+ cells from patients with
atopic dermatitis (AD) were signiﬁcantly higher than in normal
individuals. The KIAA0603 gene encodes a 1299 amino acid
protein with two phosphotyrosine interaction domains at the N-
terminal region and a TBC domain at the C-terminal region. The
region containing the TBC domain has a 31% homology to
human rab6 GTPase activating protein (GAP). When human
primary CD3+ cells were stimulated with anti-CD3 or calcium
ionophore, the KIAA0603 transcript level was upregulated. The
marked upregulation of KIAA0607 was accompanied by activa-
tion induced cell death of primary CD3+ cells. KIAA0603 is
likely to be a Rab GAP that participates in the regulation of
activated T cells, especially helper memory T cells. Expression of
KIAA0603 in T cells may be involved in pathogenesis of AD.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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T cells orchestrate immune responses against antigenic
challenges. The Th2 subset of helper T cells produces Th2
cytokines, such as IL-4, IL-5 and IL-13, that play critical roles
in the pathogenesis of allergic diseases. Atopic dermatitis (AD)
is a chronic and relapsing inﬂammatory skin disease that is
characterized by pruritus, elevated serum IgE levels, and pe-
ripheral blood eosinophilia. A two-phase model of the path-
ogenesis of AD has been proposed, in which T cells play an
immunoregulatory role in both the physiologic and pathologic
immune responses. An AD episode is initiated by an inﬂam-
matory response in which the Th2 cells predominate. The ec-* Corresponding author. Present address: Tanabe Seiyaku Co., Ltd., 2-
2-50 Kawagishi, Toda, Saitama 335-8505, Japan. Fax: +81-48-433-
8163.
E-mail address: oshidata@tanabe.co.jp (T. Oshida).
Abbreviations: AD, atopic dermatitis; GAP, GTPase activating pro-
tein; G protein, GTP binding protein; PBMC, peripheral blood
mononuclear cell; DD, diﬀerential display analysis; AICD, activation
induced cell death
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doi:10.1016/j.febslet.2004.07.023zematous phase that follows is dominated by Th1 cells, which
produce IL-2 and IFN-c [1,2].
Allergic diseases are complex because multiple genes are
thought to be involved, as well as environmental factors. We
have analyzed transcription proﬁles in peripheral blood im-
mune cells from patients with allergic diseases and found many
genes that were diﬀerentially expressed when patients and
healthy individuals were compared [3,4].
During diﬀerential gene expression analysis of human pe-
ripheral blood CD3+ cells from patients with allergic diseases,
such as AD and asthma, we observed that the expression levels
of the gene, KIAA0603, were higher in AD patients than in
healthy controls. The deduced amino acid sequence of
KIAA0603 showed homology to GTPase activation proteins
(GAP). The Ras superfamily of small GTP-binding proteins
(G protein) comprises a large group of proteins involved in
signal transduction, proliferation, vesicle traﬃcking, and reg-
ulation of the actin cytoskeleton. The G protein is activated by
GTP binding and inactivated when the bound GTP is con-
verted to GDP. The G protein has GTPase activity that is
enhanced by GAP. GAP is involved in conversion of the G
protein to the inactivated form [5].
We describe the identiﬁcation and analysis of the expression
proﬁles of KIAA0603 in CD3+ cells from allergic patients.
Transcriptional upregulation of KIAA0603 after stimulation
through the T cell receptor, especially during induction of
apoptosis, is discussed.2. Materials and methods
2.1. Study population
Patients with allergic disease and healthy individuals were both re-
cruited for participation in the study. Patient proﬁles and clinical pa-
rameters have been described in detail [3]. Patients with AD were
diagnosed according to the criteria of Haniﬁn [6]. Diagnosis of atopic
asthma and classiﬁcation of asthma severity were based on the asthma
prevention and management guidelines [7]. Written informed consent
to participate in the study was obtained from all subjects. The conduct
of the study was in accordance with the guidelines established in the
National Research Institute for Child Health and Development.
2.2. Identiﬁcation of KIAA0603 gene by diﬀerential display analysis
The methods for diﬀerential display analysis (DD) of human pe-
ripheral blood T cells from allergic patients have been described in
detail [3]. A slightly modiﬁed version of the ﬂuorescent diﬀerential
display method described by Ito et al. [8] was used in this study.blished by Elsevier B.V. All rights reserved.
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ferent primer sets in a combination of 30-anchored oligo-dT primers
and arbitrary decamer primers. The DNA fragment that was obtained
by DD PCR was further elongated by PCR cloning using a kit based
on the 50-RACE method (Clontech, Palo Alto, CA, USA). A human
leukocyte cDNA (Clontech) was used as a template for PCR.
2.3. Preparation of leukocyte cDNA samples
Peripheral blood mononuclear cells (PBMCs) were prepared from
10–20 ml of venous blood. After dextran sedimentation, white cells
were separated using standard methods for Ficoll-Hypaque gradient
centrifugation. CD3+ cells were isolated using a magnetic cell sorter
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The per-
centage of CD3+ T cells was >97%. CD16-negative eosinophils, ob-
tained from the sedimented granulocyte fraction of the Ficoll-Hypaque
gradients, were isolated by negative selection using a magnetic cell
sorter. The percentage of eosinophils was >97%. CD14+ monocytes
were prepared from cells remaining after separation of CD3+ cells.
The cells remaining after separation of CD14+ cells were the source of
B cells. CD16+ granulocytes remaining after separation of CD16) cells
were the source of neutrophils. Total RNA was prepared using an
RNA extraction kit (RNeasy Mini, Qiagen GmbH, Hilden, Germany).
DNase-treated total RNAs were mixed with oligo (dT)12–18 primer or
random primers and ﬁrst strand cDNAs were synthesized using Su-
perScript II reverse transcriptase.
2.4. Preparation of T cell subsets
CD8+ cells were prepared from PBMCs of a healthy volunteer by
magnetic sorting. CD4+ cells were isolated using CD4 multisort mi-
crobeads (Miltenyi Biotec) from cells remaining after separation of
CD8+ cells. After removing the magnetic particles from the CD4+
cells, CD45RA+ cells were isolated. The CD45RO+ cells were pre-
pared from the cells remaining after separation of CD45RA+ cells.
2.5. Real time quantitative RT-PCR
Real time RT-PCR for quantitation of gene expression was per-
formed using an ABI PRISM 7700 Sequence Detection System (PE
Applied Biosystems, USA). Based on the ORF of KIAA0603, primers
and a dual-labeled ﬂuorogenic probe (TaqMan Probe) were designed
using the computer program Primer Express 1.0 (PE Applied
Biosystems, Foster City, USA). The primer sequences were 50-AA-
GACAGTGGAGCAACTCCGG-30 (forward) and 50-CAGCAAC-
AGGTCACAATTGGC-30 (reverse) and the probe sequence was
50-AGCTGCTGCCCGCGGATGCT-30. The quantitative PCR was
performed using a TaqMan PCR Reagent Kit according to the man-
ufacturer’s protocol (PE Applied Biosystems). Sample cDNAs,
equivalent to 5 ng of starting RNA, were used for each reaction in a
96-well PCR plate. The fragment that was PCR ampliﬁed from the
human leukocyte cDNA library template by using the forward and
reverse primers was cloned into a plasmid. The resulting plasmid DNA
was used to prepare absolute standards.
Levels of b-actin mRNA were used as an internal standard for each
sample. b-actin was quantiﬁed in each freshly isolated sample as an
absolute value. The copy number of b-actin was averaged for all such
samples and the ratio of absolute to average b-actin values was used to
normalize the copy number of the target sequence. For in vitro ex-
periments using primary T cells, ribosomal RNA was used for an in-
ternal standard instead of b-actin. Quantity of ribosomal RNA was
measured using commercially available control reagents (VIC probe,
PE Applied Biosystems).
2.6. Northern blot hybridization
Commercially available Northern blot analysis membranes (human
MTN Blot, Clontech) were used to analyze human tissues for
KIAA0603 mRNA. Plasmid clone HG01488 containing the complete
coding region of KIAA0603 was obtained from Kazusa DNA Research
Institute. The plasmid DNA was labeled with 32dCTP using a random
primer labeling kit (Takara, Kyoto, Japan) and used as probe. Hy-
bridization was carried out using ExpressHybTM Hybridization Solu-
tion (Clontech) as described in the manufacturer’s protocol.
2.7. Activation-induced cell death of T cells
CD3+ cells were isolated from PBMCs and maintained in RPMI
1640 medium supplemented with 5% FCS, 2mM L-glutamine, 1 mM
sodium pyruvate, penicillin (100 U/ml) and streptomycin (100 lg/ml).For the ﬁrst activation, CD3+ cells (5· 105 cells/ml) were placed into
6-well plates that had been pre-coated with 10 lg/ml of CD3 mono-
clonal antibody (mAb, Orthoclone OKT3, Ortho Biotech, South Ra-
ritan, USA) and cultured using media both with and without 100 U/ml
of IL-2, for various time periods before analysis of gene expression.
For the second activation, cells were initially activated at a density of
1 · 105 cells/ml, using media with IL-2 (200 U/ml). After a 5-day ex-
pansion period, the cells were harvested and re-incubated for addi-
tional 3 days in medium containing 200 U/ml IL-2. For the second
activation, cells were harvested and placed into anti-CD3 coated 6-well
plates in medium containing 200 U/ml IL-2. For stimulation with
ionomycin (1 lg/ml), cells were incubated in plates without anti-CD3.
Cell viability was determined by trypan blue exclusion.
2.8. Modeling of tertiary structure of KIAA0603
Models of protein KIAA0603 were generated based on the homol-
ogy modeling method. PSI-Blast was ﬁrst used to ﬁnd templates in the
PDB95 database. Modeler [9] was then used to create a model based
on the PSI-blast alignment. To evaluate the quality of the model, the
scores from Proﬁle 3D and PMF methods were combined to verify the
score [10–12].
2.9. Statistical analysis
Statistical analysis was computer-based and used StatView 5 soft-
ware (SAS Institute, Cary, NC, USA). The t-test was used for com-
parisons between the normal controls and patient groups. When
multiple comparisons were made between groups, signiﬁcant between-
group variability was ﬁrst established using the ANOVA. The Fisher’s
PLSD was then used for intergroup comparisons. Probability values of
P < 0:05 were accepted as signiﬁcant.3. Results
3.1. Isolation of DNA fragment by diﬀerential display analysis
Peripheral blood CD3+ cells were prepared from 59 subjects
(12 healthy volunteers, 23 AD patients, and 24 asthmatic pa-
tients). A 164 bp DNA fragment that was ampliﬁed using an
anchor primer 50-GT15C-30 and an arbitrary primer 50-
TCTCTGGAGT-30 was identiﬁed as being expressed at a
higher level in allergic patients than in normal individuals in
the DD PCR. To conﬁrm the result of DD study, the tran-
scription level of the 164 bp DNA fragment in the same RNA
samples was examined with quantitative RT-PCR. The 164 bp
DNA fragment was expressed at a signiﬁcantly higher level in
the AD patients than in the healthy controls (P < 0:05, data
not shown).
The 164 bp DNA fragment was further elongated to obtain
a DNA fragment of 486 bp. A BLAST search on a public
database revealed that position 27–255 of the 486 bp nucleo-
tide sequence had 100% identity to the cDNA of KIAA0603
(GenBank Accession No. AB011175), previously identiﬁed by
the Kazusa DNA Research Institute [13]. Furthermore, the
486 bp sequence was completely identical to the nucleotides
128071–127586 (reverse strand) of the genome sequence (Ac-
cession No. AL162571) that encodes KIAA0603 gene on
chromosome 13. The 164 bp DD fragment was considered to
be derived from the immature mRNA intron region of
KIAA0603 gene. The KIAA0603/AS160 protein is the product
of the human TBC1D4 gene that maps to 13q21.33.
3.2. Structure analysis of KIAA0603
The deduced KIAA0603 aa sequence encoded a protein of
1299 residues, which had two phosphotyrosine interaction
domains (167–237 and 415–487 aa) at the N-terminal region
and a TBC domain (965–1184 aa) at the C-terminal region
(Fig. 1A). The full amino acid sequence of KIAA0603/human
Fig. 1. Domain and tertiary structures of KIAA0603. (A) Two phos-
photyrosine interaction domains (PID) are indicated by slashed boxes
and a TBC domain present in KIAA0603 is indicated by a dotted box.
The region analyzed for the tertiary structure is indicated by a red
underline. (B) The tertiary structure of KIAA0603 (913–1167 aa) was
generated based on the homology modeling method using the tertiary
structure of Gyp1p protein. The Arg973 residue of KIAA0603 protein
and the corresponding Arg343 residue of Gyp1p, that is an essential
GTAase activating site, are both shown in yellow within the structure
model and indicated by arrows within panel B.
Fig. 2. Expression of KIAA0603 mRNA in various human tissues.
Northern blot analysis of human tissues probed with the 32dCTP la-
beled plasmid DNA encoding the entire sequence of KIAA0603. RNA
kb molecular size markers are shown on the left. The b-actin probe was
hybridized to the same blot for comparison and is shown at the bottom
of each blot.
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mouse Tbc1 (Accession No. T29104; 45% identity in 1238 aa
residues) and human TBC1D1/KIAA1108 (Accession No.
AB029031; 51% identity in 819 aa residues). Tbc1, the mouse
ortholog of human TBC1D1, also contains phosphotyrosine
interaction domains and a TBC domain, indicating the close
relationship of these genes. The TBC domain was ﬁrst identi-
ﬁed as a homologous region commonly present in Tbc1, the
tre-2 oncogene and the yeast cell cycle regulators BUB2 and
cdc16 [14]. The 52–584 aa region of KIAA0603 and the related
1–478 aa region of mouse Tbc1 have 43% homology. Similarly,
the 738–1256 aa region of KIAA0603 and the related 585–1094
aa region of Tbc1 show 58% homology. The region containing
the TBC domain (886–1237aa) showed homology of 31% to
human rab6 GAP (Accession No. NP 036329).
The 913–1167 aa region had a 21% homology to yeast
Gyp1p protein (Accession No. NP 014713), which has a
known crystal structure [15]. The tertiary structure of
KIAA0603 was generated by the homology modeling method
and using the tertiary structure of Gyp1p protein as a basis.
KIAA0603 protein (913 – 1167 aa) was predicted to have a
tertiary structure similar to the GTPase activating site struc-
ture of Gyp1p protein. Arg973 residue of KIAA0603 protein
corresponds to Arg343 residue of Gyp1p, which is essential to
the GTAase activating site (Fig. 1B).
3.3. Expression of KIAA0603 in tissues
An approximately 6 kb mRNA was detected in a survey of
human tissues when the mRNA blots were hybridized with the
KIAA0603 probe. The mRNA was identical in size to the
cloned KIAA0603 cDNA (5922 bp). Abundant expression was
observed in heart and skeletal muscle. An additional 5 kbmRNA was also observed in the immune tissues, such as
spleen, lymph node and leukocyte. The 5 kb mRNA expression
was higher than that of the 6 kb mRNA in tissues from spleen
and lymph node (Fig. 2).
3.4. Transcription levels in T cells from AD patients
To reconﬁrm the result of diﬀerential expression analysis of
the 164 bp DNA fragment, the transcription levels of
KIAA0603 in the CD3+ cells from AD patients were measured
by quantitative PCR using primers and a probe designed from
the ORF region. Because the cDNA samples used for the DD
study were no longer available, transcription levels were
measured in another set of cDNA samples that were prepared
previously and independent of the DD study. The set consisted
of individual cDNAs from CD3+ cells of 10 healthy volunteers
and 30 AD patients [3]. KIAA0603 mRNA was expressed at a
signiﬁcantly higher level in T cells from a group of 30 AD
patients that included all severities of disease than in T cells
from healthy controls (P < 0:05). In addition, the expression
levels were higher in patients with moderate pathology as
compared to healthy subjects (P < 0:01, Fig. 3A).
3.5. Transcription levels of KIAA0603 in leukocyte subsets
RNA samples were prepared from T cells, B cells, eosin-
ophils, monocytes, and neutrophils of ﬁve healthy subjects for
quantiﬁcation of KIAA0603 transcripts. The expression level
was highest in T cells (Fig. 3B). The expression was higher in
cells from CD4+ T cell subset than in CD8+ cells. The ex-
pression was also higher in the helper, memory CD45RO+
subset of CD4+ cells than in CD45RA+ cells (Fig. 3C).
3.6. Upregulation of KIAA0603 in T cell activation
We have previously identiﬁed the ETEA gene, which is up-
regulated in T cells of AD patients and possibly involved in
apoptosis[16]. To examine the involvement of KIAA0603 in T
cell activation and activation induced cell death (AICD), the
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Fig. 3. Transcription levels of KIAA0603 in peripheral blood leuko-
cytes. (A) KIAA0603 transcription levels in CD3+ cells from healthy
controls and AD patients with either mild, moderate or severe disease
diagnosis. *, P < 0:05; **, P < 0:01. Results are shown as means
S.D. (B) Transcription levels of KIAA0603 were examined in subsets
of PBMCs from ﬁve healthy individuals. Results are shown as
meansS.D. (C) Transcription levels of KIAA0603 were examined in
subsets of T cells from a healthy individual. Results shown are rep-
resentatives of 2 independent experiments.
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Fig. 4. Upregulation of KIAA0603 transcription levels during stimu-
lation of primary CD3+ cells. (A) First activation. Freshly prepared
CD3+ cells were stimulated with anti-CD3 (closed circles), anti-
CD3+IL-2 (open circles), or 100 U/ml of IL2 (crosses). Controls are
shown as closed triangles. Total RNA was extracted from each sample.
The transcription levels of KIAA0603 were measured by real time RT-
PCR and normalized to ribosomal RNA. Results shown are repre-
sentatives of 2 independent experiments. (B) Induction of apoptosis. In
the second activation of T cells, viable cells were counted by a trypan
blue exclusion method. Cells treated with anti-CD3 (closed circles) and
controls (closed triangles) are shown. Each value represents
mean S.D. Results shown are representatives of 3 independent ex-
periments. (C) Second activation. CD3 cells expanded by anti-CD3
stimulation were re-stimulated with anti-CD3 (closed circles). Closed
triangles are controls. Total RNA was extracted from each sample and
the transcription levels of KIAA0603 were measured by real time RT-
PCR. Each value represents meanS.D. Results shown are repre-
sentatives of 3 independent experiments.
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during the course of activation of T cells freshly isolated from
peripheral blood. The transcription level of KIAA0603 was
transiently upregulated at 5 h after the ﬁrst in vitro stimulation
with mAb to CD3 (Fig. 4A). A 37% AICD was induced 49 h
after the second stimulation of primary peripheral blood T
cells with CD3 mAb (Fig. 4B). The transcription level of
KIAA0603 was markedly upregulated at 2 h after the stimu-
lation. The elevated levels gradually declined but at 21 h were
still higher than the unstimulated control (Fig. 4C). In similar
experiments, the expression of KIAA0603 was shown to be
markedly induced by stimulation with 1 lg/ml of ionomycin
(data not shown).4. Discussion
Using diﬀerential gene expression analysis of CD3+ cells, we
found that the expression levels of KIAA0603 were higher in
AD patients than in healthy individuals. The expression level
of the intron 164 bp DNA fragment in asthmatic patients was
not signiﬁcantly higher than in the healthy controls. This
suggests that upregulation of KIAA0603 may be associated
Y. Matsumoto et al. / FEBS Letters 572 (2004) 135–140 139with AD, but not allergic asthma. To clarify this point, it is
important to understand the KIAA0603 mRNA levels in
asthmatic patients.
The expression level of KIAA0603 was higher in patients
with moderate pathology as compared to healthy controls. In
our previous study, we have identiﬁed several genes, including
MAR/SAR DNA-binding protein and heat shock protein 40,
that were also expressed at signiﬁcantly higher levels in mod-
erate AD patients than in healthy controls [3]. The relevance of
these genes to severity of AD is uncertain. The upregulation of
KIAA0603 might reﬂect accelerated AICD in T cells of pa-
tients with moderate AD.
Analysis of secondary and tertiary structure of KIAA0603
gave results that were compatible with an assignment to a
family of Rab GAPs. A database surveillance for genes pre-
dicting proteins related to GAP identiﬁed KIAA0603 as a
RabGAP that contained both a phosphotyrosine-binding do-
main(s) and a TBC domain and was most closely related to the
Drosophila ortholog, pollux [17]. Rab GTPases are the largest
group of the Ras superfamily of small monomeric G proteins.
The Rab proteins have been implicated in the regulation of
various transport steps in both the endocytic and exocytic
pathway. They are potential regulators of transport vesicle
budding and delivery to their correct target compartments [18].
The GTPase proteins cycle between biologically active GTP-
bound and inactive GDP-bound conformations. GAPs inac-
tivate the GTP-binding proteins by enhancing their intrinsi-
cally low GTPase activity. Rab proteins are thought to
contribute to polarized secretion during the course of T cell
activation. Upon encountering a B cell, Th2 cells rearrange the
cytoskeleton and release IL-4 in a polarized fashion over the
area of receptor crosslinking [19]. In cell-mediated cytotoxic-
ity, conjugate formation between CD8+ and target cells is
accompanied by capping of the adhesion molecule LFA-1 in
the contact area. Simultaneously, the Golgi apparatus and the
microtubule organizing center polarize toward the point of
contact, resulting in a directed release of cytotoxic eﬀector
molecules [20].
When primary T cells were stimulated through the T cell
receptor in our experiments, the transcriptional levels of
KIAA0603 were upregulated. In particular, marked upregula-
tion and sustained expression of KIAA0603 was observed in
the course of AICD. It is generally assumed that GAPs are
speciﬁc for GTPases that are within their own branch of the
Ras superfamily. In addition, several GAPs are speciﬁc for a
subset of GTAases within the branch [17]. The upregulation of
KIAA0603may be involved in the modulation of the activity of
a KIAA0603-related Rab GTPase protein.
Recently, Kane et al. [21] identiﬁed KIAA0603 (gi7662198:
TBC1 domain family, member 4), which they designated
AS160, as a substrate for Akt protein kinase in adipocytes.
They demonstrated that insulin-stimulated phosphorylation of
AS160 is required for GLUT4 translocation and hypothesized
that insulin-stimulated translocation of GLUT4 requires a
Rab in its active GTP form. Phosphorylation of AS160 in-
hibits its GAP activity toward the Rab. Consequently, the
GTP form of the Rab increases and the Rab-dependent steps
in GLUT4 translocation can proceed [22].
There is considerable evidence that Akt is activated with the
co-stimulation through CD28 and functions as an important
mediator of T cell survival. Functions of Akt are transcrip-
tional upregulation of the anti-apoptotic molecule Bcl-XLthrough activation of NFkB, phosphorylation resulting in in-
hibition of the pro-apoptotic molecule BAD, and inhibition of
Fas-mediated apoptosis. When T cells are repeatedly stimu-
lated through a T cell receptor without co-stimulation by
CD28, AICD is induced. AICD is thought to be a feedback
mechanism for terminating an ongoing immune response [23],
as well as means of inducing peripheral tolerance.
In our previous study of expression kinetics of apoptosis-
related genes during AICD induced by anti-CD3 stimulation,
pro-apoptic genes such as Fas, Bax and FAF1 were upregu-
lated and the elevated levels were maintained until 48h. In
contrast, the transient upregulation of anti-apoptic genes (Bcl2
and BclXL) was followed by downregulation at 48 h [16].
During AICD, the transcription kinetics of KIAA0603 were
similar to those of pro-apoptic genes. Since co-stimulation
through CD28, the predominant activator of PI3K/PKB
pathway [24], was not present in this experiment, the PKB was
considered to be inactive. Therefore, the PKB substrate
KIAA0603/AS160 was in an activated, unphosphorylated
form, which led to inactivation of Rab proteins. The corre-
sponding Rab protein may have a role in the activation and
survival of T cells. Therefore, the upregulation and accumu-
lation of the activated form of KIAA0603 may be involved in
the induction of AICD by inactivating Rab proteins.
Very recently, Akdis et al. [25] reported that circulating
cutaneous lymphocyte associated antigen-bearing (CLA+)
CD45RO+ T cells undergo AICD in patients with AD. In
particular, the Th1 subset of CLA+ CD45RO+ T cells selec-
tively undergoes AICD, skewing the immune response toward
surviving Th2 cells in AD. Because mRNA levels of
KIAA0603 were strongly upregulated in the course of AICD
of primary T cells, the higher expression of KIAA0603 in
CD4+ CD45RO+ T cells that we observed probably reﬂects
the AICD of Th1 subset of CLA+ CD45RO+ T cells.
The apoptosis of CLA+ CD45RO+ T cells was conﬁned to
atopic individuals. Non-atopic patient, such as psoriasis and
healthy controls, showed no evidence of enhanced T cell ap-
optosis in vivo [25]. Psoriasis is a dermatological disorder in
which Th1 cells are dominant. Based on the reported results,
we can speculate that the expression level of KIAA0603 is not
upregulated in T cells of patients with psoriasis. Further
studies of the expression level of KIAA0603 in psoriasis should
conﬁrm this hypothesis.
In summary, we have found that the transcription levels of
KIAA0603 were signiﬁcantly higher in AD patients than in
normal individuals. KIAA0603, a Rab GAP, probably par-
ticipates in modulation of activation and AICD of T cells,
especially memory helper T cells, by interacting with a corre-
sponding Rab protein(s). Our data point to the possible in-
volvement of KIAA0603 in the pathogenesis of AD.
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